Leading PBM claims that 2018 formulary delivers $2.5 billion in savings

2 August 2017

Express Scripts (Nasdaq: ESRX), the USA’s largest pharmaceutical benefits manager (PBM), has published its National Preferred Formulary (NPF) for 2018.

More Americans obtain their pharmacy benefit coverage through the NPF than any other formulary, meaning that the list of which drugs are included and excluded has real significance for the industry.

PBMs seek to save money for payers by excluding over-priced drugs from the list where possible while preserving access, and Express Scripts claims to have delivered $7.4 million in year-over-year client savings in the last five years through formulary exclusions.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK